EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study

Endre Gabrielsen, Tom Wilsgaard, Hanne Frydenberg, Trygve Lofterød, Stig Manfred Dalen, Elin Mortensen, Marit D Solbu, Hawa Nalwoga, Lars A Akslen, Egil S Blix, Hege S Haugnes

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-025-07786-4 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Endre Gabrielsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, UiT - The Arctic University of Norway, 9037, Tromsø, Norway. endre.gabrielsen@unn.no. Hauptthemen laut MEDLINE: Breast Neoplasms, Syndecan-4, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Northern Norway Regional Health Authority, UiT The Arctic University of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Syndecans are transmembrane proteins involved in inflammation and signaling pathways. Their potential role as pre-diagnostic biomarkers for breast cancer risk remains unexplored. This study aimed to investigate whether pre-diagnostic serum syndecan levels are associated with breast cancer risk in a population-based cohort.

Methods

We conducted a case-cohort study nested within the Tromsø Study (Norway), including women who participated in the fifth survey (2001). Women with incident breast cancer (cases, n = 158) through 2022 were identified, with a random sub-cohort of 708 women. Serum levels of syndecan-1 (SDC1) and syndecan-4 (SDC4) were measured using ELISA on frozen serum samples obtained in 2001. All participants were stratified into quartiles (Q1–Q4) based on pre-diagnostic levels. Cox proportional hazards regression models assessed associations between serum syndecan levels and breast cancer risk.

Results

The median age at diagnosis was 69 years for cases, and 83.3% of tumors were hormone receptor-positive (HR +). Women with higher serum SDC4 (Q2–Q4) levels had approximately a twofold increased risk of breast cancer compared to women in Q1. We observed a nearly threefold increased risk for the HR + subtype. In postmenopausal women, HRs for HR + breast cancer in Q2, Q3, and Q4 were 3.81 (95% CI: 1.57–9.23), 3.43 (95% CI: 1.41–8.40), and 3.54 (95% CI: 1.45–8.65), respectively, all relative to Q1 of SDC4. No associations were observed between SDC1 levels and breast cancer risk.

Conclusions

Our results suggest that SDC4 may play a role in the initiation and early progression of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSyndecan-4Biomarkers, TumorHumansFemaleAgedMiddle AgedNorwayCase-Control StudiesRisk FactorsSyndecan-1Cohort StudiesAdult

Stichwörter der Autor:innen

Breast cancerCase-cohort studyHormone receptor-positiveRisk factorsSyndecan 1Syndecan 4

Substanzen

Syndecan-4Biomarkers, TumorSDC4 protein, humanSyndecan-1SDC1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Medicine, UiT - The Arctic University of Norway, 9037, Tromsø, Norway. endre.gabrielsen@unn.no.
  • Department of Oncology, University Hospital of North Norway, 9038, Tromsø, Norway. endre.gabrielsen@unn.no.
  • Department of Community Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Department of Pathology, University Hospital of North Norway, Tromsø, Norway.
  • Department of Medical Biology, UiT - The Arctic University of Norway, Tromsø, Norway.

Förderung

  • The Northern Norway Regional Health Authority
  • UiT The Arctic University of Norway

Zitieren

APA

Gabrielsen, E., Wilsgaard, T., Frydenberg, H., Lofterød, T., Dalen, S. M., Mortensen, E., Solbu, M. D., Nalwoga, H., Akslen, L. A., Blix, E. S., & Haugnes, H. S. (2025). Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07786-4

Vancouver

Gabrielsen E, Wilsgaard T, Frydenberg H, Lofterød T, Dalen SM, Mortensen E, et al. Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-025-07786-4

BibTeX
@article{Gabrielsen2025,
  author = {Gabrielsen, Endre and Wilsgaard, Tom and Frydenberg, Hanne and Lofterød, Trygve and Dalen, Stig Manfred and Mortensen, Elin and Solbu, Marit D and Nalwoga, Hawa and Akslen, Lars A and Blix, Egil S and Haugnes, Hege S},
  title = {Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-025-07786-4}
}
Kostenlos starten →